The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Animals
Antineoplastic Agents
/ pharmacology
CTLA-4 Antigen
/ antagonists & inhibitors
Humans
Immunotherapy
/ methods
Melanoma
/ drug therapy
Molecular Targeted Therapy
/ methods
Mutation
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Randomized Controlled Trials as Topic
Binimetinib
CTLA-4
Cobimetinib
Combination
Dabrafenib
Encorafenib
Immunotherapy
Ipilimumab
Melanoma
Nivolumab
PD-1
Pembrolizumab
Sequencing
Targeted therapy
Trametinib
Vemurafenib
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
29 07 2019
29 07 2019
Historique:
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
25
8
2020
Statut:
epublish
Résumé
The treatment of advanced melanoma has changed dramatically in recent years with several new drugs having been approved for the treatment of melanoma since 2011. This review aims to evaluate the role of BRAF-targeted therapy for advanced melanoma in the immunotherapy era. Currently, in patients with BRAF wild-type advanced melanoma, anti-PD-1 (nivolumab or pembrolizumab) is the main treatment. The combination of nivolumab and ipilimumab (anti-CTLA-4) is also an important option for these patients, resulting in a better outcome, but with less favorable toxicity profile. In patients with BRAF mutations, three regimens of BRAF plus MEK inhibitors are now approved (vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib), which achieve rapid antitumor responses and a significant survival benefit. In these patients, as well as in BRAF wild-type patients, immunotherapy can be also effective and is regularly used. Immunotherapy and targeted therapy have become the new standards of care, substantially improving survival rates. However, many questions still remain unanswered, such as what is the best first- and second-line treatment and the best treatment sequence. New combinations of drugs, targeted therapy combined with immunotherapy, and sequencing approaches are now underway in many ongoing clinical trials.
Identifiants
pubmed: 31359162
doi: 10.1007/s11912-019-0827-x
pii: 10.1007/s11912-019-0827-x
doi:
Substances chimiques
Antineoplastic Agents
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Références
Nature. 2001 Mar 1;410(6824):37-40
pubmed: 11242034
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Nature. 2006 Jan 19;439(7074):358-62
pubmed: 16273091
J Clin Oncol. 2008 Feb 1;26(4):527-34
pubmed: 18235113
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6
pubmed: 19915144
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nature. 2010 Dec 16;468(7326):968-72
pubmed: 21107320
Nature. 2010 Dec 16;468(7326):973-7
pubmed: 21107323
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Nature. 2011 Nov 23;480(7377):387-90
pubmed: 22113612
Curr Opin Immunol. 2012 Apr;24(2):207-12
pubmed: 22236695
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
J Transl Med. 2013 Mar 08;11:61
pubmed: 23497384
N Engl J Med. 2013 Apr 4;368(14):1365-6
pubmed: 23550685
Cancer Invest. 2014 May;32(4):144-9
pubmed: 24484235
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Cancer. 2014 Jun 1;120(11):1695-701
pubmed: 24577748
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
J Transl Med. 2014 May 07;12:116
pubmed: 24885479
Lancet Oncol. 2014 Aug;15(9):954-65
pubmed: 25037139
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Melanoma Res. 2015 Feb;25(1):68-74
pubmed: 25396684
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Ann Oncol. 2015 Mar;26(3):573-82
pubmed: 25524477
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2
pubmed: 25996827
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Eur J Cancer. 2015 Nov;51(17):2689-97
pubmed: 26364516
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Oncoimmunology. 2017 Jan 19;6(3):e1283462
pubmed: 28405510
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
Eur J Cancer. 2017 Sep;82:45-55
pubmed: 28648698
Cancer Res. 2017 Sep 1;77(17):4684-4696
pubmed: 28652244
Lancet Oncol. 2017 Sep;18(9):1202-1210
pubmed: 28729151
Eur J Cancer. 2017 Sep;83:247-257
pubmed: 28756137
J Transl Med. 2017 Aug 8;15(1):173
pubmed: 28789707
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Eur J Cancer. 2017 Nov;86:37-45
pubmed: 28961465
J Clin Oncol. 2018 Feb 1;36(4):391-398
pubmed: 29040030
Int J Cancer. 2018 May 15;142(10):2139-2152
pubmed: 29243224
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Lancet Oncol. 2018 Oct;19(10):1315-1327
pubmed: 30219628
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243